Try LifeScience Products:
AI-Powered
Pharmaceutical Intelligence
Access to drugs, clinical trials, patents, literatures and news in one search
Try:
AL-102 (Ayala)Crohn DiseasePneumococcal InfectionsFGFRL1APOC3Pfizer Inc.
85
K
Drugs & Biologics
46
K
Targets
977
K
Organizations
922
K
/
171
K
Clinical Trials / Results
66
M
Literatures
16
M
Patents
Recent blog posts
View all blog posts →
What is ED50?
"What" Series
2 min read
What is ED50?
24 April 2024
ED50 (Effective Dose 50) refers to the dose of a drug or substance that produces a desired effect in 50% of a population or sample under a given set of experimental conditions or in a group of test subjects.
Read →
EU Commission Approves BIMZELX® for Hidradenitis Suppurativa, First Biologic Targeting IL-17A and IL-17F
Latest Hotspot
3 min read
EU Commission Approves BIMZELX® for Hidradenitis Suppurativa, First Biologic Targeting IL-17A and IL-17F
24 April 2024
The European Commission has granted UCB approval for BIMZELX®(bimekizumab), marking it as the initial biologic targeting both IL-17A and IL-17F for treating moderate to severe hidradenitis suppurativa.
Read →
Tavapadon: A New Hope in the Battle Against Parkinson's Disease
Hot Spotlight
7 min read
Tavapadon: A New Hope in the Battle Against Parkinson's Disease
24 April 2024
The challenge is finding how to effectively alleviate these symptoms while maintaining sufficient safety. Tavapadon has found a balance in addressing this issue.
Read →
Check out our latest report
View all reports →
Global Drug R&D Express (Jan 2024)

Global Drug R&D Express (Jan 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 68 drugs. Among them, 2 first-to-market drugs and 3 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →
Global Drug R&D Express (Dec 2023)

Global Drug R&D Express (Dec 2023)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 104 drugs. Among them, 2 first-to-market drugs and 5 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →
Global Drug R&D Express (Nov 2023)

Global Drug R&D Express (Nov 2023)

This report compiles and summarizes the basic information of all the first-to-market and special-review medicines globally in November, totaling 104. From these, 5 first-to-market medicines and 5 special-review medicines have been meticulously selected. The report provides a detailed interpretation of these medicines, covering multiple aspects such as their basic information, development status, technological barriers, mechanisms of action, clinical trials, and competitive landscape.

Read →
Latest news
View all news →
news cover
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
23 Apr 2024
news cover
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
21 hours ago
news cover
Excision BioTherapeutics Announces Oral Presentation Highlighting Positive Data from its HBV Program, EBT-107, at the Upcoming ASGCT 2024 Annual Meeting
23 Apr 2024
news cover
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
23 Apr 2024
Who We Serve
View our solutions →
01
R&D Decision Makers
R&D Decision Makers
We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.
02
Business Development Professionals
Business Development Professionals
We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.
03
Pharmaceutical Analyst
Pharmaceutical Analyst
We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!
LifeScience Product Suite
Synapse
Looking for drug development opportunities
Evaluate the value of license-in projects
Screen investment targets
Optimize product pipeline
Current product
Bio
Chase new frontiers in bio-innovation
Stay on top of competitor movements
Validate novelty and freedom to operate searches with ease
Identify sequences for therapeutic activities
View details
Chemical
Explore promising compounds and their applications
Accelerate novelty and freedom to operate reviews
Strengthen competitor analysis
View details
Get started for free today!
Access to drugs, clinical trials, patents, literatures and news in one search.